Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI are starting a book club! We will be reading/discussing non-technical books relevant to our roles. Participants will be split into smaller groups to network with each other and practice exercises.
The first talk will be about "Introduction to Statistical Methods and Challenges in Vaccine Development" by Ivan Chan and the second talk will be about "Vaccine quintet. Statistical issues in the design and analysis of five vaccine programmes" by Stephen Senn.
In this short course, we will provide a statistical framework to incorporate external information into a trial. Bayesian Dynamic Borrowing designs based on the meta-analytic predictive (MAP) model will be detailed, and a practice session will be proposed with applications using the R package RBesT.
Our annual PSI Medical Statistics Careers Event, will be held online on Wednesday 2nd March 2022. The event will include a live online panel discussion and a virtual exhibition session.
We offer challenging work in a respectful and friendly global working environment surrounded by a world of innovation driven mindsets and practices.
In this role you will consult in the design of complex and innovative studies and clinical trial programs as well as Leading DMC/DSMB processes.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, decision making, analytics and interpretation.
Joining us as Principal Biostatistician you will be responsible for providing statistical support of global clinical development programs in neuroscience.
